Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 10(63), 2019

DOI: 10.1128/aac.00913-19

Links

Tools

Export citation

Search in Google Scholar

Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans

Journal article published in 2019 by Elizabeth W. Tucker ORCID, Lisa Pieterse, Matthew D. Zimmerman, Zarir F. Udwadia, Charles A. Peloquin ORCID, Maria Tarcela Gler, Shashank Ganatra ORCID, Jeffrey A. Tornheim, Prerna Chawla, Janice C. Caoili, Brittaney Ritchie, Sanjay K. Jain, Véronique Dartois ORCID, Kelly E. Dooley
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Central nervous system tuberculosis (TB) is devastating and affects vulnerable populations. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculous meningitis (TBM) specifically are nearly uniformly fatal, with little information being available to guide the treatment of these patients. Delamanid (DLM), a nitro-dihydro-imidazooxazole, is a new, well-tolerated anti-TB drug with a low MIC (1 to 12 ng/ml) against Mycobacterium tuberculosis .